search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Are you doing enough to protect your spinal referrals?


The volume of spinal procedures being performed in the outpatient setting has increased massively over the past decade, with a twofold increase in the incidence of outpatient ACDF cases alone from 2007 to 2016.1


However, a recent study1 of over 12,000 patients who were tracked


longitudinally using the PearlDiver database found that compared to in-patients, those treated with ACDF in the outpatient clinic were:


> 50% more likely to need an anterior fusion > 70% more likely to require conversion


within 12 months1 to posterior fusion within 12 months1 Avoid your referral rate being aff ected by latest data


These are alarming outcomes considering patient selection for the outpatient setting would naturally favor improved outcomes for ACDF compared to an inpatient cohort.1


technologies to support their ambulatory surgical care practice.


We spoke with Faheem Sandhu, MD, PhD, who specializes in minimally invasive and complex spinal surgery at both inpatient and outpatient clinics and said of his practice:


“ Using the newest minimally invasive techniques enables me to provide relief for people who previously might not have been good candidates for spine surgery, such as older or obese individuals. This includes performing increasingly complex spinal fusions in our ambulatory surgical care center.


It’s important I have access to the best equipment, implants and biologics to support this change in care pathway. This latest study in The Spine Journal highlights the importance of choosing the most effective technologies when performing fusion surgery in ambulatory centers.”


Choosing the most eff ective bone graft can improve spine fusion outcomes by up to 60%2, 3


If there is one thing that you can do overnight to have the biggest eff ect on your fusion outcomes, it’s to evaluate your bone graft of choice. Kuros Biosciences has developed MagnetOs to deliver reliable fusion through predictable bone formation.4, 5


Surgeons are turning to cutting-edge Success is in the surface


Unlike fi rst generation bone grafts, the advanced surface of MagnetOs has needle-shaped features. They are submicron in size and ideal for the attachment and spreading of macrophages. When human macrophages are exposed to MagnetOs, they are polarized to the M2 phenotype, reliably leading to the formation of new bone instead of scar tissue.6, *


MagnetOs can promote bone in soft tissues without added cells or growth factors6, *, ¥


This promotes bone formation simultaneously throughout the fusion bed, for a uniform, strong and stable fusion.4, 5, 7, *


Vitoss® BA2X MagnetOs™


Instrumented posterolateral fusion in sheep, 12w post-implantation (instrumentation has been subtracted from reconstruction; coloring highlights fusion mass containing new bone and graft: Grey = Vitoss BA2X, purple = MagnetOs)


Uniform, strong and stable fusion4, 5


In recent preclinical studies, multiple assessments at the 12-week mark showed MagnetOs had a 100% fusion rate,5, 7, *


fusion rate for both Vitoss BA2X & Novabone Putty.7, * Choose MagnetOs to protect your referrals


Contact Kuros to fi nd out more about how MagnetOs can deliver predictable outcomes for your patients and protect your center’s spinal referral rate. Email Kuros today: cs@kurosbio.com


1. The Spine Journal 18 (2018) 1180–1187 2. Morris MT, et al. European Spine Journal 2018;27:1856-1867 3. Hsu WK, et al. Global Spine J 2012;2:239–248 4. Van Dijk LA, et al. JOR Spine 2018;e1039. 5. Van Dijk LA, et al. J Biomed Mater Res B Part B 2019:9999B:1–11 6. Duan R, et al. Eur Cell Mater 2019;37:60-73 7. Data on fi le. * Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans ¥ MagnetOs is not cleared by FDA as an osteoinductive bone graft. Please see the Instructions for Use for a full list of indications, contraindications, warnings and cautions. Manufactured by Kuros Biosciences BV, Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands. PROMO/MAG/US/007-19/R00 29 Mar 2019.


in comparison with a 33%


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38